Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Bad
|
New words:
acceleration, alleviate, attractive, billed, blocking, discretionary, doubt, elarekibep, Fibrogen, footage, gene, goblet, Immunotherapy, interacting, Mabcalin, mucin, Notch, pamrevlumab, plugging, secretory, signaling, suggest, surface, TM, usage
Removed:
costimulatory, deadline, ERS, Freising, moved, passed, record, refundable, safe
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view